Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04505254
Title Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors M.D. Anderson Cancer Center
Indications

chronic lymphocytic leukemia/small lymphocytic lymphoma

Therapies

Acalabrutinib + Obinutuzumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.